Article
Pharmacology & Pharmacy
Antonietta G. Gravina, Kateryna Priadko, Lucia Granata, Angela Facchiano, Giuseppe Scida, Rosa Cerbone, Paola Ciamarra, Marco Romano
Summary: In this study, BQT using Pylera demonstrated to be an effective therapeutic strategy with high eradication rates of H. pylori in areas with high prevalence of CLA or CLA + metronidazole resistance strains. The treatment showed good compliance and low incidence of side effects, making it a suitable option for patients naive to treatment in such regions.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Gastroenterology & Hepatology
Xiao-Jian He, Xiang-Peng Zeng, Chuan-Shen Jiang, Gang Liu, Da-Zhou Li, Wen Wang
Summary: The study results suggest that antofloxacin may be a promising candidate for rescue therapy in cases of Helicobacter pylori eradication failure in China, with significantly higher eradication rates compared to levofloxacin. Both groups exhibited similar rates of adverse events.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Article
Medicine, General & Internal
Maria Pina Dore, Francesco Saba, Lucia Zanni, Anna Rocca, Jessica Piroddu, Giuseppe Gutierrez, Giovanni Mario Pes
Summary: This study aimed to investigate the efficacy of a low-dose 10-day quadruple therapy containing bismuth salicylate for Helicobacter pylori infection. The results showed that this treatment regimen provided high eradication rates of H. pylori infection, with minimal side effects.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Zhiqiang Song, Baojun Suo, Xueli Tian, Xinlu Ren, Yan Xue, Zhanyue Niu, Liya Zhou
Summary: This study aimed to determine whether tailored triple plus bismuth therapy (TBT) based on previous medication history can achieve higher eradication rates for H. pylori compared to empiric TBT. The results showed that tailored TBT based on previous antibiotic history achieved significantly higher eradication rates than clarithromycin-, levofloxacin-, and metronidazole-containing empiric TBT, indicating that tailored therapy based on past medication history can improve H. pylori eradication rates.
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Gastroenterology & Hepatology
Kallirroi Kotilea, Samy Cadranel, Assaad Salame, Julie Nguyen, Tania Mahler, Veronique Yvette Miendje Deyi, Laurine Verset, Patrick Bontems
Summary: The 10-day quadruple therapy containing CBS, ESO, AMO, and MET is a safe and effective treatment for H. pylori eradication in children, especially for previously treated patients and those infected with double resistant strains.
Article
Pharmacology & Pharmacy
Zinan Zhang, Fen Liu, Feiyan Ai, Xiong Chen, Rui Liu, Chao Zhang, Ning Fang, Tian Fu, Xiaoyan Wang, Anliu Tang
Summary: The purpose of this study was to evaluate the safety and efficacy of a 14-day VPZ-containing triple therapy in the Chinese population and explore the potential mechanism. The results showed that VPZ-containing triple therapy had a higher eradication rate for H. pylori, with no significant differences in medication adherence or the incidence of adverse events. VPZ had no direct inhibitory effect on H. pylori, while EPZ may inhibit H. pylori through downregulated genes related to the ribosome.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Health Care Sciences & Services
Nikola Perkovic, Antonio Mestrovic, Josko Bozic, Mirela Pavicic Ivelja, Jonatan Vukovic, Goran Kardum, Zeljko Sundov, Marija Tonkic, Zeljko Puljiz, Katarina Vukojevic, Ante Tonkic
Summary: Tailored therapy for H. pylori infection achieves higher eradication rates with lower adverse events compared to concomitant therapy, making it a reasonable choice for first-line treatment as antibiotic resistance increases.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Qin Ma, Hancong Li, Jing Liao, Zhaolun Cai, Bo Zhang
Summary: Tailored therapy may provide a better eradication rate than empirical therapy in first-line treatment for H. pylori infection, but there may be no obvious advantage in second-line or mixed second- and third-line treatments. The results have a high level of heterogeneity and further clinical studies are warranted.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Gastroenterology & Hepatology
Yeon-Ji Kim, Woo Chul Chung, Dae Bum Kim
Summary: The study found that adding bismuth to standard triple therapy can be an effective first-line treatment regimen for Helicobacter pylori eradication, especially in patients with clarithromycin-resistant strains. Although the eradication rate in resistant strains was lower, it still remains a viable treatment option.
Article
Immunology
Jinnan Chen, Yixian Guo, Yu Huang, Zhaohui Ding, Jing Wang, Xiao Liang, Ping Xu, Yaohua Han, Hong Lu
Summary: The study compared the efficacy and safety of rifabutin-containing triple therapy with bismuth quadruple therapy for rescue treatment of Helicobacter pylori. The results showed that rifabutin triple therapy is an alternative to classical bismuth quadruple therapy for the rescue treatment of H. pylori, with fewer side effects and higher compliance.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Gastroenterology & Hepatology
Ying Zhou, Ziqing Ye, Yuhuan Wang, Zhiheng Huang, Cuifang Zheng, Jieru Shi, Wenjuan Tang, Ping Zhang, Shengnan Wang, Ying Huang
Summary: Eradication of H. pylori infection can cause transient dysbiosis in gut microbiota, but these changes mostly recover within a year post-eradication, indicating the long-term safety of H. pylori therapy.
Article
Medicine, General & Internal
Baojun Suo, Xueli Tian, Hua Zhang, Haoping Lu, Cailing Li, Yuxin Zhang, Xinlu Ren, Xingyu Yao, Liya Zhou, Zhiqiang Song
Summary: This study compared the efficacy, safety, and compliance of minocycline-containing bismuth quadruple therapy (BQT) and tetracycline-containing BQT as first-line regimens for Helicobacter pylori eradication. The results showed that the eradication rates, adverse events, and compliance were similar between the two groups.
CHINESE MEDICAL JOURNAL
(2023)
Article
Gastroenterology & Hepatology
Giuseppe Losurdo, Maria Pricci, Margherita De Bellis, Francesca Celiberto, Francesco Russo, Giuseppe Riezzo, Benedetta D'attoma, Andrea Iannone, Maria Rendina, Enzo Ierardi, Alfredo Di Leo
Summary: The study evaluated the impact of metronidazole resistance on the eradication therapy of H. pylori and found that metronidazole resistance does not affect the eradication rates of BQT and CT regimens in our geographical area.
JOURNAL OF DIGESTIVE DISEASES
(2022)
Article
Pharmacology & Pharmacy
Qinyu Yang, Cong He, Yi Hu, Junbo Hong, Zhenhua Zhu, Yong Xie, Xu Shu, Nonghua Lu, Yin Zhu
Summary: This study investigated whether high-dose dual therapy could be used as a first-line treatment for Helicobacter pylori infection in elderly patients. The results showed that high-dose dual therapy had a similar eradication rate to bismuth-containing quadruple therapy, but with fewer side effects.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Microbiology
Younghee Choe, Joon Sung Kim, Hyun Ho Choi, Dae Bum Kim, Jae Myung Park, Jung Hwan Oh, Tae Ho Kim, Dae Young Cheung, Woo Chul Chung, Byung-Wook Kim, Sung Soo Kim
Summary: This study found that past exposure to metronidazole significantly reduced the eradication rate of bismuth quadruple therapy (BQT), suggesting that a 14-day course of BQT should be recommended for patients suspected of metronidazole exposure.
FRONTIERS IN MICROBIOLOGY
(2022)